ASH 2021 | Efficacy of VenDd vs DVd in patients with t(11;14) R/R myeloma
In this video, Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, briefly highlights some preliminary findings from a Phase I study on patients with relapsed multiple myeloma. Following this, Dr Kaufman gives a detailed update on results from a 3-part Phase I/II randomized continuation of this study (NCT03314181). In his discussion, Dr Kaufman compares the use of two doses of venetoclax, daratumumab and dexamethasone (VenDd) versus a combination of bortezomib, daratumumab and dexamethasone (DVd) in patients with t(11;14) positive relapsed and/or refractory (R/R) myeloma. Dr Kaufman explains the benefits observed, including overall response rate and infection rate, providing context from a safety and efficacy perspective. Dr Kaufman also mentions the potential use of this data for a future Phase III trial. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
